Glucovance

[Glyburide/Metformin]

Mean Final Dose 0 mg 5.3 mg 1317 mg 2.78 mg/ 557 mg 4.1 mg/ 824 mg
Number (%) of patients with 5 (3.1) 34 (21.3) 5 (3.1) 18 (11.4) 61 (37.7)

symptoms of hypoglycemia

Number (%) of 39 (24.2) 38 (23.8) 69 (43.3) 50 (31.6) 62 (38.3) patients with gastrointestinal adverse events

Text Continues Below

---

Drug Interactions

GLUCOVANCE

Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block-ing drugs, and isoniazid. When such drugs are administered to a patient receiving GLUCOVANCE, the patient should be closely observed for loss of blood glucose control. When such drugs are with-drawn from a patient receiving GLUCOVANCE, the patient should be observed closely for hypo-glycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact.

Page:  << Prev | 1 | 2 | 3